Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers

Autoimmunity Reviews

Volumn 15, Issue 11, 2016, Pages 1013-1030

  López Mejías, Raquel ^a   Castañeda, Santos ^b   González Juanatey, Carlos ^c   Corrales, Alfonso ^a   Ferraz Amaro, Iván ^d   Genre, Fernanda ^a   Remuzgo Martínez, Sara ^a   Rodriguez Rodriguez, Luis ^e   Blanco, Ricardo ^a   Llorca, Javier ^f   Martín, Javier ^g   González Gay, Miguel A ^a,f,h  

^a Division of Epidemiology   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c Hospital Lucus Augusti   (Spain)

^d HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f UNIVERSITY OF CANTABRIA   (Spain)

^g INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^h UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Atherosclerosis; Cardiovascular risk; Carotid ultrasonography; Genetics; Rheumatoid arthritis; Serum biomarkers

Indexed keywords

ADIPOCYTOKINE; BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE; HLA ANTIGEN; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR; VITAMIN D; AUTACOID; HLA DRB1 ANTIGEN;

CARDIOVASCULAR RISK; CELL ACTIVATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE MARKER; ENDOTHELIUM CELL; GENE; GENETIC ASSOCIATION; GENETIC MARKER; GENOTYPING TECHNIQUE; HUMAN; INFLAMMATION; INNATE IMMUNITY; LIPID METABOLISM; METABOLIC SYNDROME X; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEROLOGY; ARTHRITIS, RHEUMATOID; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; GENETICS; RISK FACTOR;

ARTHRITIS, RHEUMATOID; BIOMARKERS; CARDIOVASCULAR DISEASES; HLA-DRB1 CHAINS; HUMANS; INFLAMMATION MEDIATORS; RISK ASSESSMENT; RISK FACTORS;

EID: 84992490317     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.07.026     Document Type: Review

References (356)

1. [1] Scott, D.L., Wolfe, F., Huizinga, T.W., Rheumatoid arthritis. Lancet 376 (2010), 1094–1108.
2. [2] Wolfe, F., Freundlich, B., Straus, W.L., Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 30 (2003), 36–40.
3. [3] Avina-Zubieta, J.A., Choi, H.K., Sadatsafavi, M., Etminan, M., Esdaile, J.M., Lacaille, D., Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59 (2008), 1690–1697.
4. [4] Goodson, N., Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 14 (2002), 115–120.
5. [5] Goodson, N.J., Symmons, D.P., Scott, D.G., Bunn, D., Lunt, M., Silman, A.J., Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year follow-up study of a primary care-based inception cohort. Arthritis Rheum 52 (2005), 2293–2299.
6. [6] Libby, P., Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 121 (2008), S21–S31.
7. [7] Maradit-Kremers, H., Crowson, C.S., Nicola, P.J., Ballman, K.V., Roger, V.L., Jacobsen, S.J., et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52 (2005), 402–411.
8. [8] Gonzalez-Gay, M.A., Gonzalez-Juanatey, C., Martin, J., Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 35 (2005), 8–17.
9. [9] Shoenfeld, Y., Gerli, R., Doria, A., Matsuura, E., Cerinic, M.M., Ronda, N., et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112 (2005), 3337–3347.
10. [10] Gonzalez, A., Maradit Kremers, H., Crowson, C.S., Ballman, K.V., Roger, V.L., Jacobsen, S.J., et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcome in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?. Ann Rheum Dis 67 (2008), 64–69.
11. [11] Stavropoulos-Kalinoglou, A., Metsios, G.S., Panoulas, V.F., Douglas, K.M., Nevill, A.M., Jamurtas, A.Z., et al. Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis 68 (2009), 242–245.
12. [12] Gerli, R., Sherer, Y., Bocci, E.B., Vaudo, G., Moscatelli, S., Shoenfeld, Y., Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors. Ann N Y Acad Sci 1108 (2007), 372–381.
13. [13] Dessein, P.H., Joffe, B.I., Veller, M.G., Stevens, B.A., Tobias, M., Reddi, K., et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 32 (2005), 435–442.
14. [14] Chung, C.P., Oeser, A., Raggi, P., Gebretsadik, T., Shintani, A.K., Sokka, T., et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 52 (2005), 3045–3053.
15. [15] Agca, R., Heslinga, S.C., van Halm, V.P., Nurmohamed, M.T., Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders. Heart 102 (2016), 790–795.
16. [16] Dessein, P.H., Norton, G.R., Woodiwiss, A.J., Joffe, B.I., Wolfe, F., Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 34 (2007), 943–951.
17. [17] Gonzalez-Gay, M.A., Gonzalez-Juanatey, C., Martin, J., Inflammation and endothelial dysfunction in rheumatoid arthritis. Clin Exp Rheumatol 24 (2006), 115–117.
18. [18] Gonzalez-Gay, M.A., Gonzalez-Juanatey, C., Piñeiro, A., Garcia-Porrua, C., Testa, A., Llorca, J., High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 32 (2005), 1219–1223.
19. [19] Gonzalez-Gay, M.A., Gonzalez-Juanatey, C., Lopez-Diaz, M.J., Piñeiro, A., Garcia-Porrua, C., Miranda-Filloy, J.A., et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 57 (2007), 125–132.
20. [20] Crowson, C.S., Gabriel, S.E., Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment. Ann Rheum Dis 70 (2011), 719–721.
21. [21] González-Gay, M.A., González-Juanatey, C., Llorca, J., Carotid ultrasound in the cardiovascular risk stratification of patients with rheumatoid arthritis: when and for whom?. Ann Rheum Dis 71 (2012), 796–798.
22. [22] Gonzalez-Juanatey, C., Llorca, J., Martin, J., Gonzalez-Gay, M.A., Carotid intima–media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum 38 (2009), 366–371.
23. [23] Evans, M.R., Escalante, A., Battafarano, D.F., Freeman, G.L., O'Leary, D.H., del Rincón, I., Carotid atherosclerosis predicts incident acute coronary syndrome in rheumatoid arthritis. Arthritis Rheum 63 (2011), 1211–1220.
24. [24] Rodríguez-Rodríguez, L., González-Juanatey, C., Palomino-Morales, R., Vázquez-Rodríguez, T.R., Miranda-Filloy, J.A., Fernández-Gutiérrez, B., et al. TNFA-308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 216 (2011), 125–130.
25. [25] López-Mejías, R., García-Bermúdez, M., González-Juanatey, C., Castañeda, S., Miranda-Filloy, J.A., Gómez-Vaquero, C., et al. NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 224 (2012), 426–429.
26. [26] Otero, M., Lago, R., Gomez, R., Lago, F., Dieguez, C., Gómez-Reino, J.J., et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 65 (2006), 1198–1201.
27. [27] Szekanecz, Z., Kerekes, G., Végh, E., Kardos, Z., Baráth, Z., Tamási, L., et al. Autoimmune atherosclerosis in 3D: How it develops, how to diagnose and what to do. Autoimmun Rev 15 (2016), 756–769.
28. [28] Bartoloni, E., Alunno, A., Bistoni, O., Gerli, R., How early is the atherosclerotic risk in rheumatoid arthritis?. Autoimmun Rev 9 (2010), 701–707.
29. [29] Solomon, D.H., Karlson, E.W., Rimm, E.B., Cannuscio, C.C., Mandl, L.A., Manson, J.E., et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107 (2003), 1303–1307.
30. [30] Sattar, N., McCarey, D.W., Capell, H., McInnes, I.B., Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108 (2003), 2957–2963.
31. [31] Ferraz-Amaro, I., González-Juanatey, C., López-Mejias, R., Riancho-Zarrabeitia, L., González-Gay, M.A., Metabolic syndrome in rheumatoid arthritis. Mediators Inflamm, 2013, 2013, 710928.
32. [32] Kerekes, G., Nurmohamed, M.T., González-Gay, M.A., Seres, I., Paragh, G., Kardos, Z., et al. Rheumatoid arthritis and metabolic syndrome. Nat Rev Rheumatol 10 (2014), 691–696.
33. [33] Nadar, S., Blann, A.D., Lip, G.Y., Endothelial dysfunction: methods of assessment and application to hypertension. Curr Pharm Des 10 (2004), 3591–3605.
34. [34] Celermajer, D.S., Sorensen, K.E., Gooch, V.M., Spiegelhalter, D.J., Miller, O.I., Sullivan, I.D., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340 (1992), 1111–1115.
35. [35] Corretti, M.C., Anderson, T.J., Benjamin, E.J., Celermajer, D., Charbonneau, F., Creager, M.A., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39 (2002), 257–265.
36. [36] Gonzalez-Juanatey, C., Testa, A., Garcia-Castelo, A., Garcia-Porrua, C., Llorca, J., Vidan, J., et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 114 (2003), 647–652.
37. [37] Vaudo, G., Marchesi, S., Gerli, R., Allegrucci, R., Giordano, A., Siepi, D., et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 63 (2004), 31–35.
38. [38] Gonzalez-Juanatey, C., Llorca, J., Testa, A., Revuelta, J., Garcia-Porrua, C., Gonzalez-Gay, M.A., Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 82 (2003), 407–413.
39. [39] Corrales, A., González-Juanatey, C., Peiró, M.E., Blanco, R., Llorca, J., González-Gay, M.A., Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis 73 (2014), 722–727.
40. [40] Corrales, A., Parra, J.A., González-Juanatey, C., Rueda-Gotor, J., Blanco, R., Llorca, J., et al. Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 72 (2013), 1764–1770.
41. [41] Salonen, J.T., Salonen, R., Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb 11 (1991), 1245–1249.
42. [42] van Sijl, A.M., Peters, M.J., Knol, D.K., de Vet, H.C., Gonzalez-Gay, M.A., Smulders, Y.M., et al. Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum 40 (2011), 389–397.
43. [43] Touboul, P.J., Hennerici, M.G., Meairs, S., Adams, H., Amarenco, P., Bornstein, N., An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 23 (2007), 75–80.
44. [44] González-Juanatey, C., Llorca, J., González-Gay, M.A., Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing disease. Arthritis Res Ther, 13, 2011, R101.
45. [45] Gonzalez-Gay, M.A., Gonzalez-Juanatey, C., Vazquez-Rodriguez, T.R., Martin, J., Llorca, J., Endothelial dysfunction, carotid intima–media thickness, and accelerated atherosclerosis in rheumatoid arthritis. Semin Arthritis Rheum 38 (2008), 67–70.
46. [46] Kerekes, G., Soltész, P., Nurmohamed, M.T., Gonzalez-Gay, M.A., Turiel, M., Végh, E., et al. Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat Rev Rheumatol 8 (2012), 224–234.
47. [47] Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature, 401, 1999, 921–923.
48. [48] Farragher, T.M., Goodson, N.J., Naseem, H., Silman, A.J., Thomson, W., Symmons, D., et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 58 (2008), 359–369.
49. [49] Mattey, D.L., Thomson, W., Ollier, W.E., Batley, M., Davies, P.G., Gough, A.K., et al. Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of follow-up from the early rheumatoid arthritis study. Arthritis Rheum 56 (2007), 1408–1416.
50. [50] Gonzalez-Gay, M.A., Gonzalez-Juanatey, C., Ollier, W.E., Endothelial dysfunction in rheumatoid arthritis: influence of HLA-DRB1 alleles. Autoimmun Rev 3 (2004), 301–304.
51. [51] Rojas-Villarraga, A., Ortega-Hernandez, O.D., Gomez, L.F., Pardo, A.L., López-Guzmán, S., Arango-Ferreira, C., et al. Risk factors associated with different stages of atherosclerosis in Colombian patients with rheumatoid arthritis. Semin Arthritis Rheum 38 (2008), 71–82.
52. [52] LeibundGut-Landmann, S., Waldburger, J.M., Krawczyk, M., Otten, L.A., Suter, T., Fontana, A., et al. Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes. Eur J Immunol 34 (2004), 1513–1525.
53. [53] Buttice, G., Miller, J., Wang, L., Smith, B.D., Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells. Circ Res 98 (2006), 472–479.
54. [54] Garcia-Bermudez, M., González-Juanatey, C., Lopez-Mejias, R., Rodriguez-Rodriguez, L., Pérez-Esteban, S., Castañeda, S., et al. Influence of MHCIITA rs3087456 and rs4774 polymorphisms in the susceptibility to cardiovascular disease of patients with rheumatoid arthritis. Clin Exp Rheumatol 30 (2012), 51–57.
55. [55] Tedgui, A., Mallat, Z., Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86 (2006), 515–581.
56. [56] Vallvé, J.C., Paredes, S., Girona, J., Uliaque, K., Ribalta, J., Hurt-Camejo, E., et al. Tumor necrosis factor-alpha − 1031 T/C polymorphism is associated with smaller and more proatherogenic low density lipoprotein particles in patients with rheumatoid arthritis. J Rheumatol 35 (2008), 1697–1703.
57. [57] Panoulas, V.F., Nikas, S.N., Smith, J.P., Douglas, K.M., Nightingale, P., Milionis, H.J., et al. Lymphotoxin 252A > G polymorphism is common and associates with myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis 67 (2008), 1550–1556.
58. [58] Genre, F., López-Mejías, R., García-Bermúdez, M., Castañeda, S., González-Juanatey, C., Llorca, J., et al. Osteoprotegerin CGA haplotype protection against cerebrovascular complications in anti-CCP negative patients with rheumatoid arthritis. PLoS One, 9, 2014, e106823.
59. [59] Ärlestig, L., Rantapää-Dahlqvist, S., Polymorphisms of the genes encoding CD40 and growth differentiation factor 15 and in the 9p21.3 region in patients with rheumatoid arthritis and cardiovascular disease. J Rheumatol 39 (2012), 939–945.
60. [60] García-Bermúdez, M., González-Juanatey, C., López-Mejías, R., Teruel, M., Corrales, A., Miranda-Filloy, J.A., et al. Study of association of CD40-CD154 gene polymorphisms with disease susceptibility and cardiovascular risk in Spanish rheumatoid arthritis patients. PLoS One, 7, 2012, e49214.
61. [61] Brennan, F.M., McInnes, I.B., Evidence that cytokines plays a role in rheumatoid arthritis. J Clin Invest 118 (2008), 3537–3545.
62. [62] McKellar, G.E., McCarey, D.W., Sattar, N., McInnes, I.B., Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol 6 (2009), 410–417.
63. [63] Abraham, L.J., Kroeger, K.M., Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol 66 (1999), 562–566.
64. [64] Hjelmstrom, P., Fjell, J., Nakagawa, T., Sacca, R., Cuff, C.A., Ruddle, N.H., Lymphoid tissue homing chemokines are expressed in chronic inflammation. Am J Pathol 156 (2000), 1133–1138.
65. [65] Tanaka, T., Ozaki, K., Inflammation as a risk factor for myocardial infarction. J Hum Genet 51 (2006), 595–604.
66. [66] Schreyer, S.A., Vick, C.M., LeBoeuf, R.C., Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice. J Biol Chem 277 (2002), 12364–12368.
67. [67] Hofbauer, L.C., Schoppet, M.C., Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292 (2004), 490–495.
68. [68] Van Campenhout, A., Golledge, J., Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 204 (2009), 321–329.
69. [69] Kiechl, S., Schett, G., Wenning, G., Redlich, K., Oberhollenzer, M., Mayr, A., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109 (2004), 2175–2180.
70. [70] Roshandel, D., Holliday, K.L., Pye, S.R., Ward, K.A., Boonen, S., Vanderschueren, D., et al. Influence of polymorphisms in the RANKL/RANK/OPG signaling pathway on volumetric bone mineral density and bone geometry at the forearm in men. Calcif Tissue Int 89 (2011), 446–455.
71. [71] Soufi, M., Schoppet, M., Sattler, A.M., Herzum, M., Maisch, B., Hofbauer, L.C., et al. Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab 89 (2004), 3764–3768.
72. [72] Biscetti, F., Straface, G., Giovannini, S., Santoliquido, A., Angelini, F., Santoro, L., et al. Association between TNFRSF11B gene polymorphisms and history of ischemic stroke in Italian diabetic patients. Hum Genet 132 (2013), 49–55.
73. [73] Straface, G., Biscetti, F., Pitocco, D., Bertoletti, G., Misuraca, M., Vincenzoni, C., et al. Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene, TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability. Stroke 42 (2011), 3022–3028.
74. [74] Nishimoto, N., Kishimoto, T., Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2 (2006), 619–626.
75. [75] Akira, S., Kishimoto, T., IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev 127 (1992), 25–50.
76. [76] Panoulas, V.F., Stavropoulos-Kalinoglou, A., Metsios, G.S., Smith, J.P., Milionis, H.J., Douglas, K.M., et al. Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis 204 (2009), 178–183.
77. [77] Palomino-Morales, R., Gonzalez-Juanatey, C., Vazquez-Rodriguez, T.R., Miranda-Filloy, J.A., Llorca, J., Martin, J., et al. Interleukin-6 gene -174 promoter polymorphism is associated with endothelial dysfunction but not with disease susceptibility in patients with rheumatoid arthritis. Clin Exp Rheumatol 27 (2009), 964–970.
78. [78] López-Mejías, R., García-Bermúdez, M., González-Juanatey, C., Castañeda, S., Pérez-Esteban, S., Miranda-Filloy, J.A., et al. Lack of association between IL6 single nucleotide polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis. Atherosclerosis 219 (2011), 655–658.
79. [79] Jones, S.A., Horiuchi, S., Topley, N., Yamamoto, N., Fuller, G.M., The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 15 (2001), 43–58.
80. [80] Müllberg, J., Oberthür, W., Lottspeich, F., Mehl, E., Dittrich, E., Graeve, L., et al. The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol 152 (1994), 4958–4968.
81. [81] Benrick, A., Jirholt, P., Wernstedt, I., Gustafsson, M., Scheller, J., Eriksson, A.L., et al. A non-conservative polymorphism in the IL-6 signal transducer (IL6ST)/gp130 is associated with myocardial infarction in a hypertensive population. Regul Pept 146 (2008), 189–196.
82. [82] López-Mejías, R., García-Bermúdez, M., González-Juanatey, C., Castañeda, S., Miranda-Filloy, J.A., Gómez-Vaquero, C., et al. Lack of association of IL6R rs2228145 and IL6ST/gp130 rs2228044 gene polymorphisms with cardiovascular disease in patients with rheumatoid arthritis. Tissue Antigens 78 (2011), 438–441.
83. [83] García-Bermúdez, M., López-Mejías, R., González-Juanatey, C., Corrales, A., Robledo, G., Castañeda, S., et al. Analysis of the interferon gamma (rs2430561, + 874T/A) functional gene variant in relation to the presence of cardiovascular events in rheumatoid arthritis. PLoS One, 7, 2012, e47166.
84. [84] Hansson, G.K., Libby, P., The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6 (2006), 508–519.
85. [85] Full, L.E., Ruisanchez, C., Monaco, C., The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther, 11, 2009, 217.
86. [86] Patel, S., Celermajer, D.S., Bao, S., Atherosclerosis-underlying inflammatory mechanisms and clinical implications. Int J Biochem Cell Biol 40 (2008), 576–580.
87. [87] Barnes, B.J., Moore, P.A., Pitha, P.M., Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem 276 (2001), 23382–23390.
88. [88] Schoenemeyer, A., Barnes, B.J., Mancl, M.E., Latz, E., Goutagny, N., Pitha, P.M., et al. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem 280 (2005), 17005–17012.
89. [89] Krausgruber, T., Blazek, K., Smallie, T., Alzabin, S., Lockstone, H., Sahgal, N., et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 12 (2011), 231–238.
90. [90] Eyre, S., Bowes, J., Diogo, D., Lee, A., Barton, A., Martin, P., et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 44 (2012), 1336–1340.
91. [91] Graham, R.R., Kozyrev, S.V., Baechler, E.C., Reddy, M.V., Plenge, R.M., Bauer, J.W., et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38 (2006), 550–555.
92. [92] García-Bermúdez, M., López-Mejías, R., Genre, F., Castañeda, S., Llorca, J., González-Juanatey, C., et al. Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis. Arthritis Res Ther, 16, 2014, R146.
93. [93] Ghoreschi, K., Laurence, A., O'Shea, J.J., Selectivity and therapeutic inhibition of kinases: to be or not to be?. Nat Immunol 10 (2009), 356–360.
94. [94] Sperati, C.J., Parekh, R.S., Berthier-Schaad, Y., Jaar, B.G., Plantinga, L., Fink, N., et al. Association of single-nucleotide polymorphisms in JAK3, STAT4, and STAT6 with new cardiovascular events in incident dialysis patients. Am J Kidney Dis 53 (2009), 845–855.
95. [95] García-Bermúdez, M., López-Mejías, R., Genre, F., Castañeda, S., Corrales, A., Llorca, J., et al. Lack of association between JAK3 gene polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis. Biomed Res Int, 2015, 2015, 318364.
96. [96] Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23 (2005), 479–490.
97. [97] Shen, J., Shang, Q., Wong, C.K., Li, E.K., Wang, S., Li, R.J., et al. IL-33 and soluble ST2 levels as novel predictors for remission and progression of carotid plaque in early rheumatoid arthritis: A prospective study. Semin Arthritis Rheum 45 (2015), 18–27.
98. [98] Guo, L., Zhou, X., Guo, X., Zhang, X., Sun, Y., Association of interleukin-33 gene single nucleotide polymorphisms with ischemic stroke in north Chinese population. BMC Med Genet, 14, 2013, 109.
99. [99] Latiano, A., Palmieri, O., Pastorelli, L., Vecchi, M., Pizarro, T.T., Bossa, F., et al. Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. PLoS One, 8, 2013, e62144.
100. [100] Li, C., Mu, R., Guo, J., Wu, X., Tu, X., Liu, X., et al. Genetic variant in IL33 is associated with susceptibility to rheumatoid arthritis. Arthritis Res Ther, 16, 2014, R105.
101. [101] Australo-Anglo-American Spondyloarthritis Consortium (TASC), Reveille, J.D., Sims, A.M., Danoy, P., Evans, D.M., Leo, P., et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 42 (2010), 123–127.
102. [102] Tu, X., Nie, S., Liao, Y., Zhang, H., Fan, Q., Xu, C., et al. The IL-33-ST2L pathway is associated with coronary artery disease in a Chinese Han population. Am J Hum Genet 93 (2013), 652–660.
103. [103] López-Mejías, R., Genre, F., Remuzgo-Martínez, S., Robustillo-Villarino, M., García-Bermúdez, M., Llorca, J., et al. Protective Role of the Interleukin 33 rs3939286 gene polymorphism in the development of subclinical atherosclerosis in rheumatoid arthritis patients. PLoS One, 10, 2015, e0143153.
104. [104] De Martin, R., Hoeth, M., Hofer-Warbinek, R., Schmid, J.A., The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 20 (2000), E83–E88.
105. [105] Baldwin, A.S., Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107 (2001), 241–246.
106. [106] Vogel, U., Jensen, M.K., Due, K.M., Rimm, E.B., Wallin, H., Nielsen, M.R., et al. The NFKB1 ATTG ins/del polymorphism and risk of coronary heart disease in three independent populations. Atherosclerosis 219 (2011), 200–204.
107. [107] Karban, A.S., Okazaki, T., Panhuysen, C.I., Gallegos, T., Potter, J.J., Bailey-Wilson, J.E., et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 13 (2004), 35–45.
108. [108] Chen, Y., Dawes, P.T., Packham, J.C., Mattey, D.L., Interaction between smoking and functional polymorphism in the TGFB1 gene is associated with ischaemic heart disease and myocardial infarction in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther, 14, 2012, R81.
109. [109] Mallat, Z., Tedgui, A., The role of transforming growth factor beta in atherosclerosis: novel insights and future perspectives. Curr Opin Lipidol 13 (2002), 523–529.
110. [110] Singh, N.N., Ramji, D.P., The role of transforming growth factor-beta in atherosclerosis. Cytokine Growth Factor Rev 17 (2006), 487–499.
111. [111] Attisano, L., Wrana, J.L., Mads and Smads in TGF beta signaling. Curr Opin Cell Biol 10 (1998), 188–194.
112. [112] Attisano, L., Wrana, J.L., Signal transduction by the TGF-beta superfamily. Science 296 (2002), 1646–1647.
113. [113] Heldin, C.H., Miyazono, K., ten Dijke, P., TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390 (1997), 465–471.
114. [114] Tone, Y., Furuuchi, K., Kojima, Y., Tykocinski, M.L., Greene, M.I., Tone, M., Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol 9 (2008), 194–202.
115. [115] Kalinina, N., Agrotis, A., Antropova, Y., Ilyinskaya, O., Smirnov, V., Tararak, E., et al. Smad expression in human atherosclerotic lesions: evidence for impaired TGF-beta/Smad signaling in smooth muscle cells of fibrofatty lesions. Arterioscler Thromb Vasc Biol 24 (2004), 1391–1396.
116. [116] Lees, C.W., Barrett, J.C., Parkes, M., Satsangi, J., New IBD genetics: common pathways with other diseases. Gut 60 (2011), 1739–1753.
117. [117] Shimizu, C., Jain, S., Davila, S., Hibberd, M.L., Lin, K.O., Molkara, D., et al. Transforming growth factor-beta signaling pathway in patients with Kawasaki disease. Circ Cardiovasc Genet 4 (2011), 16–25.
118. [118] García-Bermúdez, M., López-Mejías, R., Genre, F., Castañeda, S., González-Juanatey, C., Llorca, J., et al. SMAD3 rs17228212 gene polymorphism is associated with reduced risk to cerebrovascular accidents and subclinical atherosclerosis in anti-CCP negative Spanish rheumatoid arthritis patients. PLoS One, 8, 2013, e77695.
119. [119] Rodríguez-Rodríguez, L., González-Juanatey, C., García-Bermúdez, M., Vázquez-Rodríguez, T.R., Miranda-Filloy, J.A., Fernández-Gutiérrez, B., et al. CCR5Delta32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study. Arthritis Res Ther, 13, 2011, R133.
120. [120] Palomino-Morales, R., Gonzalez-Juanatey, C., Vazquez-Rodriguez, T.R., Torres, O., Miranda-Filloy, J.A., Llorca, J., et al. Lack of association between macrophage migration inhibitory factor-173 gene polymorphism with disease susceptibility and cardiovascular risk in rheumatoid arthritis patients from northwestern Spain. Clin Exp Rheumatol 28 (2010), 68–72.
121. [121] Radstake, T.R., Fransen, J., van Riel, P.L., Toonen, E., Coenen, M., Donn, R., Functional variants of the macrophage migration inhibitory factor do not infer risk of cardiovascular disease in rheumatoid arthritis. Ann Rheum Dis 67 (2008), 134–135.
122. [122] Jones, K.L., Maguire, J.J., Davenport, A.P., Chemokine receptor CCR5: from AIDS to atherosclerosis. Br J Pharmacol 162 (2011), 1453–1469.
123. [123] Samson, M., Libert, F., Doranz, B.J., Rucker, J., Liesnard, C., Farber, C.M., et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382 (1996), 722–725.
124. [124] Benkirane, M., Jin, D.Y., Chun, R.F., Koup, R.A., Jeang, K.T., Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J Biol Chem 272 (1997), 30603–30606.
125. [125] Pacheco, S.E., Gibbs, R.A., Ansari-Lari, A., Rogers, P., Intranasal immunization with HIV reverse transcriptase: effect of dose in the induction of helper T cell type 1 and 2 immunity. AIDS Res Hum Retroviruses 16 (2000), 2009–2017.
126. [126] Apostolakis, S., Baritaki, S., Kochiadakis, G.E., Igoumenidis, N.E., Panutsopulos, D., Spandidos, D.A., Effects of polymorphisms in chemokine ligands and receptors on susceptibility to coronary artery disease. Thromb Res 119 (2007), 63–71.
127. [127] Ghilardi, G., Biondi, M.L., Turri, O., Pateri, F., d'Eril, G.M., Scorza, R., Genetic control of chemokines in severe human internal carotid artery stenosis. Cytokine 41 (2008), 24–28.
128. [128] González, P., Alvarez, R., Batalla, A., Reguero, J.R., Alvarez, V., Astudillo, A., et al. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun 2 (2001), 191–195.
129. [129] Petrkova, J., Cermakova, Z., Lukl, J., Petrek, M., CC chemokine receptor 5 (CCR5) deletion polymorphism does not protect Czech males against early myocardial infarction. J Intern Med 257 (2005), 564–566.
130. [130] Szalai, C., Duba, J., Prohászka, Z., Kalina, A., Szabó, T., Nagy, B., et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 158 (2001), 233–239.
131. [131] Gómez-Reino, J.J., Pablos, J.L., Carreira, P.E., Santiago, B., Serrano, L., Vicario, J.L., et al. Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. Arthritis Rheum 42 (1999), 989–992.
132. [132] Kohem, C.L., Brenol, J.C., Xavier, R.M., Bredemeier, M., Brenol, C.V., Dedavid e Silva, T.L., et al. The chemokine receptor CCR5 genetic polymorphism and expression in rheumatoid arthritis patients. Scand J Rheumatol 36 (2007), 359–364.
133. [133] Prahalad, S., Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun 7 (2006), 264–268.
134. [134] Zernecke, A., Bernhagen, J., Weber, C., Macrophage migration inhibitory factor in cardiovascular disease. Circulation 117 (2008), 1594–1602.
135. [135] Bernhagen, J., Krohn, R., Lue, H., Gregory, J.L., Zernecke, A., Koenen, R.R., et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 13 (2007), 587–596.
136. [136] Genre, F., López-Mejías, R., Miranda-Filloy, J.A., Ubilla, B., Carnero-López, B., Blanco, R., et al. Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis. Biomed Res Int, 2014, 2014, 860651.
137. [137] Lago, F., Dieguez, C., Gómez-Reino, J., Gualillo, O., The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 18 (2007), 313–325.
138. [138] Gómez, R., Conde, J., Scotece, M., Gómez-Reino, J.J., Lago, F., Gualillo, O., What's new in our understanding of the role of adipokines in rheumatic diseases?. Nat Rev Rheumatol 7 (2011), 528–536.
139. [139] Gualillo, O., González-Juanatey, J.R., Lago, F., The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med 17 (2007), 275–283.
140. [140] Scotece, M., Conde, J., Gómez, R., López, V., Pino, J., González, A., et al. Role of adipokines in atherosclerosis: interferences with cardiovascular complications in rheumatic diseases. Mediators Inflamm, 2012, 2012, 125458.
141. [141] Oh, D.K., Ciaraldi, T., Henry, R.R., Adiponectin in health and disease. Diabetes Obes Metab 9 (2007), 282–289.
142. [142] Deng, Y., Scherer, P.E., Scherer. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci 1212 (2010), E1–E19.
143. [143] Gonzalez-Gay, M.A., Llorca, J., Garcia-Unzueta, M.T., Gonzalez-Juanatey, C., De Matias, J.M., Martin, J., et al. High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin Exp Rheumatol 26 (2008), 596–603.
144. [144] Chiodini, B.D., Specchia, C., Gori, F., Barlera, S., D'Orazio, A., Pietri, S., et al. Adiponectin gene polymorphisms and their effect on the risk of myocardial infarction and type 2 diabetes: an association study in an Italian population. Ther Adv Cardiovasc Dis 4 (2010), 223–230.
145. [145] Gable, D.R., Matin, J., Whittall, R., Cakmak, H., Li, K.W., Cooper, J., et al. Common adiponectin gene variants show different effects on risk of cardiovascular disease and type 2 diabetes in European subjects. Ann Hum Genet 71 (2007), 453–466.
146. [146] Hoefle, G., Muendlein, A., Saely, C.H., Risch, L., Rein, P., Koch, L., et al. The -11377 C > G promoter variant of the adiponectin gene, prevalence of coronary atherosclerosis, and incidence of vascular events in men. Thromb Haemost 97 (2007), 451–457.
147. [147] Liu, F., He, Z., Deng, S., Zhang, H., Li, N., Xu, J., Association of adiponectin gene polymorphisms with the risk of ischemic stroke in a Chinese Han population. Mol Biol Rep 38 (2011), 1983–1988.
148. [148] Menzaghi, C., Trischitta, V., Doria, A., Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes 56 (2007), 1198–1209.
149. [149] Patel, S., Flyvbjerg, A., Kozàkovà, M., Frystyk, J., Ibrahim, I.M., Petrie, J.R., et al. Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects. Eur Heart J 29 (2008), 386–393.
150. [150] Rodríguez-Rodríguez, L., García-Bermúdez, M., González-Juanatey, C., Vazquez-Rodriguez, T.R., Miranda-Filloy, J.A., Fernandez-Gutierrez, B., et al. Lack of association between ADIPOQ rs266729 and ADIPOQ rs1501299 polymorphisms and cardiovascular disease in rheumatoid arthritis patients. Tissue Antigens 77 (2011), 74–78.
151. [151] Tilg, H., Moschen, A.R., Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6 (2006), 772–783.
152. [152] Gainsford, T., Willson, T.A., Metcalf, D., Handman, E., McFarlane, C., Ng, A., et al. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc Natl Acad Sci U S A 93 (1996), 14564–14568.
153. [153] Lord, G.M., Matarese, G., Howard, J.K., Baker, R.J., Bloom, S.R., Lechler, R.I., Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 394 (1998), 897–901.
154. [154] Gonzalez-Gay, M.A., Garcia-Unzueta, M.T., Berja, A., Gonzalez-Juanatey, C., Miranda-Filloy, J.A., Vazquez-Rodriguez, T.R., et al. Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clin Exp Rheumatol 27 (2009), 222–228.
155. [155] Hager, J., Clement, K., Francke, S., Dina, C., Raison, J., Lahlou, N., et al. A polymorphism in the 5’ untranslated region of the human ob gene is associated with low leptin levels. Int J Obes Relat Metab Disord 22 (1998), 200–205.
156. [156] Li, W.D., Reed, D.R., Lee, J.H., Xu, W., Kilker, R.L., Sodam, B.R., et al. Sequence variants in the 5’ flanking region of the leptin gene are associated with obesity in women. Ann Hum Genet 63 (1999), 227–234.
157. [157] García-Bermúdez, M., González-Juanatey, C., Rodríguez-Rodríguez, L., Vazquez-Rodriguez, T.R., Miranda-Filloy, J.A., Fernández-Gutierrez, B., et al. Lack of association between LEP rs2167270 (19 G > A) polymorphism and disease susceptibility and cardiovascular disease in patients with rheumatoid arthritis. Clin Exp Rheumatol 29 (2011), 293–298.
158. [158] Neumann, E., Frommer, K.W., Vasile, M., Müller-Ladner, U., Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases?. Arthritis Rheum 63 (2011), 1159–1169.
159. [159] Patel, L., Buckels, A.C., Kinghorn, I.J., Murdock, P.R., Holbrook, J.D., Plumpton, C., et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 300 (2003), 472–476.
160. [160] Hartman, H.B., Hu, X., Tyler, K.X., Dalal, C.K., Lazar, M.A., Mechanisms regulating adipocyte expression of resistin. J Biol Chem 277 (2002), 19754–19761.
161. [161] Kaser, S., Kaser, A., Sandhofer, A., Ebenbichler, C.F., Tilg, H., Patsch, J.R., Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 309 (2003), 286–290.
162. [162] Gonzalez-Gay, M.A., Garcia-Unzueta, M.T., Gonzalez-Juanatey, C., Miranda-Filloy, J.A., Vazquez-Rodriguez, T.R., De Matias, J.M., et al. Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 26 (2008), 311–316.
163. [163] Kunnari, A., Ukkola, O., Kesäniemi, Y.A., Resistin polymorphisms are associated with cerebrovascular disease in Finnish Type 2 diabetic patients. Diabet Med 22 (2005), 583–589.
164. [164] Tsukahara, T., Nakashima, E., Watarai, A., Hamada, Y., Naruse, K., Kamiya, H., et al. Polymorphism in resistin promoter region at -420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients. Diabetes Res Clin Pract 84 (2009), 179–186.
165. [165] Rodriguez-Rodriguez, L., Garcia-Bermudez, M., Gonzalez-Juanatey, C., Vazquez-Rodriguez, T.R., Miranda-Filloy, J.A., Fernandez-Gutierrez, B., et al. Lack of association between RETN rs1862513 polymorphism and cardiovascular disease in rheumatoid arthritis patients. Clin Exp Rheumatol 29 (2011), 19–25.
166. [166] Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307 (2005), 426–430.
167. [167] Berndt, J., Klöting, N., Kralisch, S., Kovacs, P., Fasshauer, M., Schön, M.R., et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54 (2005), 2911–2916.
168. [168] Moschen, A.R., Kaser, A., Enrich, B., Mosheimer, B., Theurl, M., Niederegger, H., et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178 (2007), 1748–1758.
169. [169] Brentano, F., Schorr, O., Ospelt, C., Stanczyk, J., Gay, R.E., Gay, S., et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 56 (2007), 2829–2839.
170. [170] García-Bermúdez, M., González-Juanatey, C., Rodríguez-Rodríguez, L., Miranda-Filloy, J.A., Perez-Esteban, S., Vazquez-Rodriguez, T.R., et al. Lack of association of NAMPT rs9770242 and rs59744560 polymorphisms with disease susceptibility and cardiovascular risk in patients with rheumatoid arthritis. Clin Exp Rheumatol 29 (2011), 681–688.
171. [171] Bailey, S.D., Loredo-Osti, J.C., Lepage, P., Faith, J., Fontaine, J., Desbiens, K.M., et al. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes 55 (2006), 2896–2902.
172. [172] Johansson, L.M., Johansson, L.E., Ridderstråle, M., The visfatin (PBEF1) G-948T gene polymorphism is associated with increased high-density lipoprotein cholesterol in obese subjects. Metabolism 57 (2008), 1558–1562.
173. [173] Björkbacka, H., Nilsson, J., Innate immunity in atherosclerosis. J Innate Immun 2 (2010), 305–306.
174. [174] Costa, L.G., Cole, T.B., Jarvik, G.P., Furlong, C.E., Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 54 (2003), 371–392.
175. [175] Durrington, P.N., Mackness, B., Mackness, M.I., Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21 (2001), 473–480.
176. [176] Mackness, M.I., Arrol, S., Durrington, P.N., Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286 (1991), 152–154.
177. [177] Bhattacharyya, T., Nicholls, S.J., Topol, E.J., Zhang, R., Yang, X., Schmitt, D., et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299 (2008), 1265–1276.
178. [178] Costa, L.G., Vitalone, A., Cole, T.B., Furlong, C.E., Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 69 (2005), 541–550.
179. [179] Charles-Schoeman, C., Lee, Y.Y., Shahbazian, A., Gorn, A.H., Fitzgerald, J., Ranganath, V.K., et al. Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis. Arthritis Rheum 65 (2013), 2765–2772.
180. [180] López-Mejías, R., Genre, F., Corrales, A., González-Juanatey, C., Ubilla, B., Llorca, J., et al. Investigation of a PON1 gene polymorphism (rs662 polymorphism) as predictor of subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 73 (2014), 1749–1750.
181. [181] Rodríguez-Carrio, J., López-Mejías, R., Alperi-López, M., López, P., Ballina-García, F.J., González-Gay, M.A.et al., Paraoxonase 1 Activity Is Modulated by the rs662 Polymorphism and IgG Anti-High-Density Lipoprotein Antibodies in Patients With Rheumatoid Arthritis: Potential Implications for Cardiovascular Disease. Arthritis Rheumatol 68 (2016), 1367–1376.
182. [182] Moore, D.D., Kato, S., Xie, W., Mangelsdorf, D.J., Schmidt, D.R., Xiao, R., et al. International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol Rev 58 (2006), 742–759.
183. [183] Ardesia, M., Ferlazzo, G., Fries, W., Vitamin D and inflammatory bowel disease. Biomed Res Int, 2015, 2015, 470805.
184. [184] Ferrarezi, D.A., Bellili-Muñoz, N., Dubois-Laforgue, D., Cheurfa, N., Lamri, A., Reis, A.F., et al. Allelic variations of the vitamin D receptor (VDR) gene are associated with increased risk of coronary artery disease in type 2 diabetics: the DIABHYCAR prospective study. Diabetes Metab 39 (2013), 263–270.
185. [185] Al-Daghri, N.M., Guerini, F.R., Al-Attas, O.S., Alokail, M.S., Alkharfy, K.M., Draz, H.M., et al. Vitamin D receptor gene polymorphisms are associated with obesity and inflammosome activity. PLoS One, 9, 2014, e102141.
186. [186] López-Mejías, R., Genre, F., Remuzgo-Martínez, S., Robledo, G., Llorca, J., Corrales, A., et al. Vitamin D receptor GATG haplotype association with atherosclerotic disease in patients with rheumatoid arthritis. Atherosclerosis 245 (2016), 139–142.
187. [187] Moreno, P.R., Purushothaman, K.R., Fuster, V., Echeverri, D., Truszczynska, H., Sharma, S.K., et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 110 (2004), 2032–2038.
188. [188] Ribatti, D., Levi-Schaffer, F., Kovanen, P.T., Inflammatory angiogenesis in atherogenesis-a double-edged sword. Ann Med 40 (2008), 606–621.
189. [189] Epstein, S.E., Stabile, E., Kinnaird, T., Lee, C.W., Clavijo, L., Burnett, M.S., Janus phenomenon: the interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis. Circulation 109 (2004), 2826–2831.
190. [190] Luttun, A., Tjwa, M., Moons, L., Wu, Y., Angelillo-Scherrer, A., Liao, F., et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8 (2002), 831–840.
191. [191] Celletti, F.L., Waugh, J.M., Amabile, P.G., Brendolan, A., Hilfiker, P.R., Dake, M.D., Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 7 (2001), 425–429.
192. [192] Neufeld, G., Cohen, T., Gengrinovitch, S., Poltorak, Z., Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13 (1999), 9–22.
193. [193] de Boer, O.J., van der Wal, A.C., Teeling, P., Becker, A.E., Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization?. Cardiovasc Res 41 (1999), 443–449.
194. [194] Dvorak, H.F., Brown, L.F., Detmar, M., Dvorak, A.M., Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146 (1995), 1029–1039.
195. [195] Kim, I., Moon, S.O., Kim, S.H., Kim, H.J., Koh, Y.S., Koh, G.Y., Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 276 (2001), 7614–7620.
196. [196] Marumo, T., Schini-Kerth, V.B., Busse, R., Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes 48 (1999), 1131–1137.
197. [197] Zhao, Q., Egashira, K., Inoue, S., Usui, M., Kitamoto, S., Ni, W., et al. Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation 105 (2002), 1110–1115.
198. [198] Lambrechts, D., Storkebaum, E., Morimoto, M., Del-Favero, J., Desmet, F., Marklund, S.L., et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34 (2003), 383–394.
199. [199] Rodríguez-Rodríguez, L., García-Bermúdez, M., González-Juanatey, C., Vazquez-Rodriguez, T.R., Miranda-Filloy, J.A., Fernández-Gutierrez, B., et al. Vascular endothelial growth factor A and cardiovascular disease in rheumatoid arthritis patients. Tissue Antigens 77 (2011), 291–297.
200. [200] Deanfield, J.E., Halcox, J.P., Rabelink, T.J., Endothelial function and dysfunction: testing and clinical relevance. Circulation 115 (2007), 1285–1295.
201. [201] Tousoulis, D., Kampoli, A.M., Tentolouris, C., Papageorgiou, N., Stefanadis, C., The role of nitric oxide on endothelial function. Curr Vasc Pharmacol 10 (2012), 4–18.
202. [202] Vallance, P., Chan, N., Endothelial function and nitric oxide: clinical relevance. Heart 85 (2001), 342–350.
203. [203] Weinberg, J.B., Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review. Mol Med 4 (1998), 557–591.
204. [204] Gonzalez-Gay, M.A., Oliver, J., Sanchez, E., Garcia-Porrua, C., Paco, L., Lopez-Nevot, M.A., et al. Association of a functional inducible nitric oxide synthase promoter variant with susceptibility to biopsy-proven giant cell arteritis. J Rheumatol 32 (2005), 2178–2182.
205. [205] Martin, J., Paco, L., Ruiz, M.P., Lopez-Nevot, M.A., Garcia-Porrua, C., Amoli, M.M., et al. Inducible nitric oxide synthase polymorphism is associated with susceptibility to Henoch–Schonlein purpura in northwestern Spain. J Rheumatol 32 (2005), 1081–1085.
206. [206] Oksel, F., Keser, G., Ozmen, M., Aksu, K., Kitapcioglu, G., Berdeli, A., et al. Endothelial nitric oxide synthase gene Glu298Asp polymorphism is associated with Behcet's disease. Clin Exp Rheumatol 24 (2006), S79–S82.
207. [207] Gonzalez-Gay, M.A., Llorca, J., Sanchez, E., Lopez-Nevot, M.A., Amoli, M.M., Garcia-Porrua, C., et al. Inducible but not endothelial nitric oxide synthase polymorphism is associated with susceptibility to rheumatoid arthritis in northwest Spain. Rheumatology (Oxford) 43 (2004), 1182–1185.
208. [208] Pascual, M., López-Nevot, M.A., Cáliz, R., Koeleman, B.P., Balsa, A., Pascual-Salcedo, D., et al. Genetic determinants of rheumatoid arthritis: the inducible nitric oxide synthase (NOS2) gene promoter polymorphism. Genes Immun 3 (2002), 299–301.
209. [209] Gonzalez-Gay, M.A., Llorca, J., Palomino-Morales, R., Gomez-Acebo, I., Gonzalez-Juanatey, C., Martin, J., Influence of nitric oxide synthase gene polymorphisms on the risk of cardiovascular events in rheumatoid arthritis. Clin Exp Rheumatol 27 (2009), 116–119.
210. [210] Hansson, G.K., Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005), 1685–1695.
211. [211] Hansson, G.K., Robertson, A.K., Söderberg-Nauclér, C., Inflammation and atherosclerosis. Annu Rev Pathol 1 (2006), 297–329.
212. [212] Lundberg, A.M., Hansson, G.K., Innate immune signals in atherosclerosis. Clin Immunol 134 (2010), 5–24.
213. [213] Björkbacka, H., Kunjathoor, V.V., Moore, K.J., Koehn, S., Ordija, C.M., Lee, M.A., et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 10 (2004), 416–421.
214. [214] Michelsen, K.S., Wong, M.H., Shah, P.K., Zhang, W., Yano, J., Doherty, T.M., et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A 101 (2004), 10679–10684.
215. [215] Moore, K.J., Freeman, M.W., Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol 26 (2006), 1702–1711.
216. [216] Mullick, A.E., Tobias, P.S., Curtiss, L.K., Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 115 (2005), 3149–3156.
217. [217] Curtiss, L.K., Tobias, P.S., Emerging role of Toll-like receptors in atherosclerosis. J Lipid Res 50 (2009), S340–S345.
218. [218] Soehnlein, O., Lindbom, L., Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol 10 (2010), 427–439.
219. [219] Castrillo, A., Joseph, S.B., Vaidya, S.A., Haberland, M., Fogelman, A.M., Cheng, G., et al. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell 12 (2003), 805–816.
220. [220] Edfeldt, K., Swedenborg, J., Hansson, G.K., Yan, Z.Q., Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105 (2002), 1158–1161.
221. [221] Xu, X.H., Shah, P.K., Faure, E., Equils, O., Thomas, L., Fishbein, M.C., et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 104 (2001), 3103–3108.
222. [222] Ameziane, N., Beillat, T., Verpillat, P., Chollet-Martin, S., Aumont, M.C., Seknadji, P., et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 23 (2003), e61–e64.
223. [223] Boekholdt, S.M., Agema, W.R., Peters, R.J., Zwinderman, A.H., van der Wall, E.E., Reitsma, P.H., et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 107 (2003), 2416–2421.
224. [224] Krutzik, S.R., Tan, B., Li, H., Ochoa, M.T., Liu, P.T., Sharfstein, S.E., et al. TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat Med 11 (2005), 653–660.
225. [225] García-Bermúdez, M., López-Mejías, R., González-Juanatey, C., Castañeda, S., Miranda-Filloy, J.A., Blanco, R., et al. Lack of association between TLR4 rs4986790 polymorphism and risk of cardiovascular disease in patients with rheumatoid arthritis. DNA Cell Biol 31 (2012), 1214–1220.
226. [226] Eisenbarth, S.C., Colegio, O.R., O'Connor, W., Sutterwala, F.S., Flavell, R.A., Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453 (2008), 1122–1126.
227. [227] Fontalba, A., Martinez-Taboada, V., Gutierrez, O., Pipaon, C., Benito, N., Balsa, A., et al. Deficiency of the NF-kappaB inhibitor caspase activating and recruitment domain 8 in patients with rheumatoid arthritis is associated with disease severity. J Immunol 179 (2007), 4867–4873.
228. [228] Kastbom, A., Johansson, M., Verma, D., Söderkvist, P., Rantapää-Dahlqvist, S., CARD8 p.C10X polymorphism is associated with inflammatory activity in early rheumatoid arthritis. Ann Rheum Dis 69 (2010), 723–726.
229. [229] García-Bermúdez, M., López-Mejías, R., González-Juanatey, C., Corrales, A., Castañeda, S., Ortiz, A.M., et al. CARD8 rs2043211 (p.C10X) polymorphism is not associated with disease susceptibility or cardiovascular events in Spanish rheumatoid arthritis patients. DNA Cell Biol 32 (2013), 28–33.
230. [230] Födinger, M., Hörl, W.H., Sunder-Plassmann, G., Molecular biology of 5,10-methylenetetrahydrofolate reductase. J Nephrol 13 (2000), 20–33.
231. [231] Frosst, P., Blom, H.J., Milos, R., Goyette, P., Sheppard, C.A., Matthews, R.G., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10 (1995), 111–113.
232. [232] Weisberg, I., Tran, P., Christensen, B., Sibani, S., Rozen, R., A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64 (1998), 169–172.
233. [233] Ganguly, P., Alam, S.F., Role of homocysteine in the development of cardiovascular disease. Nutr J, 14, 2015, 6.
234. [234] Rubini, M., Padovan, M., Baricordi, O., Fotinidi, M., Govoni, M., Trotta, F., The c.1298A > C polymorphism in the methylenetetrahydrofolate reductase gene is associated with rheumatoid arthritis susceptibility in Italian patients. Clin Exp Rheumatol, 26, 2008, 163.
235. [235] Palomino-Morales, R., Gonzalez-Juanatey, C., Vazquez-Rodriguez, T.R., Rodriguez, L., Miranda-Filloy, J.A., Fernandez-Gutierrez, B., et al. A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis. Arthritis Res Ther, 12, 2010, R71.
236. [236] Remuzgo-Martínez, S., Genre, F., López-Mejías, R., Ubilla, B., Mijares, V., Pina, T., et al. Decreased expression of methylene tetrahydrofolate reductase (MTHFR) gene in patients with rheumatoid arthritis. Clin Exp Rheumatol 34 (2016), 106–110.
237. [237] Kim, H.Y., Gladyshev, V.N., Methionine sulfoxide reductases: selenoprotein forms and roles in antioxidant protein repair in mammals. Biochem J 407 (2007), 321–329.
238. [238] Schallreuter, K.U., Rübsam, K., Gibbons, N.C., Maitland, D.J., Chavan, B., Zothner, C., et al. Methionine sulfoxide reductases A and B are deactivated by hydrogen peroxide (H2O2) in the epidermis of patients with vitiligo. J Invest Dermatol 128 (2008), 808–815.
239. [239] García-Bermúdez, M., López-Mejías, R., González-Juanatey, C., Castañeda, S., Miranda-Filloy, J.A., Blanco, R., et al. Association of the methionine sulfoxide reductase A rs10903323 gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis. Scand J Rheumatol 41 (2012), 350–353.
240. [240] Baatar, D., Patel, K., Taub, D.D., The effects of ghrelin on inflammation and the immune system. Mol Cell Endocrinol 340 (2011), 44–58.
241. [241] Tschöp, M., Weyer, C., Tataranni, P.A., Devanarayan, V., Ravussin, E., Heiman, M.L., Circulating ghrelin levels are decreased in human obesity. Diabetes 50 (2001), 707–709.
242. [242] Dixit, V.D., Schaffer, E.M., Pyle, R.S., Collins, G.D., Sakthivel, S.K., Palaniappan, R., et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 114 (2004), 57–66.
243. [243] Li, W.G., Gavrila, D., Liu, X., Wang, L., Gunnlaugsson, S., Stoll, L.L., et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation 109 (2004), 2221–2226.
244. [244] Baessler, A., Fischer, M., Mayer, B., Koehler, M., Wiedmann, S., Stark, K., et al. Epistatic interaction between haplotypes of the ghrelin ligand and receptor genes influence susceptibility to myocardial infarction and coronary artery disease. Hum Mol Genet 16 (2007), 887–899.
245. [245] Rodríguez-Rodríguez, L., García-Bermúdez, M., Gonzalez-Juanatey, C., Vazquez-Rodriguez, T.R., Miranda-Filloy, J.A., Fernandez-Gutierrez, B., et al. Analysis of the influence of the ghrelin receptor rs509035, rs512692 and rs2922126 polymorphisms in the risk of cardiovascular disease in patients with rheumatoid arthritis. Clin Exp Rheumatol 29 (2011), 142–143.
246. [246] Bottini, N., Bottini, E., Gloria-Bottini, F., Mustelin, T., Low-molecular-weight protein tyrosine phosphatase and human disease: in search of biochemical mechanisms. Arch Immunol Ther Exp (Warsz) 50 (2002), 95–104.
247. [247] Dissing, J., Immunochemical characterization of human red cell acid phosphatase isozyMetS. Biochem Genet 25 (1987), 901–918.
248. [248] Souza, A.C., Azoubel, S., Queiroz, K.C., Peppelenbosch, M.P., Ferreira, C.V., From immune response to cancer: a spot on the low molecular weight protein tyrosine phosphatase. Cell Mol Life Sci 66 (2009), 1140–1153.
249. [249] Chiarugi, P., Cirri, P., Raugei, G., Manao, G., Taddei, L., Ramponi, G., Low M(r) phosphotyrosine protein phosphatase interacts with the PDGF receptor directly via its catalytic site. Biochem Biophys Res Commun 219 (1996), 21–25.
250. [250] Bottini, N., Stefanini, L., Williams, S., Alonso, A., Jascur, T., Abraham, R.T., et al. Activation of ZAP-70 through specific dephosphorylation at the inhibitory Tyr-292 by the low molecular weight phosphotyrosine phosphatase (LMPTP). J Biol Chem 277 (2002), 24220–24224.
251. [251] Bottini, E., Gloria-Bottini, F., Borgiani, P., ACP1 and human adaptability. 1. Association with common diseases: a case–control study. Hum Genet 96 (1995), 629–637.
252. [252] Banci, M., Saccucci, P., D'Annibale, F., Dofcaci, A., Trionfera, G., Magrini, A., et al. ACP1 genetic polymorphism and coronary artery disease: an association study. Cardiology 113 (2009), 236–242.
253. [253] Teruel, M., Martin, J.E., González-Juanatey, C., López-Mejias, R., Miranda-Filloy, J.A., Blanco, et al. Association of acid phosphatase locus 1*C allele with the risk of cardiovascular events in rheumatoid arthritis patients. Arthritis Res Ther, 13, 2011, R116.
254. [254] Begovich, A.B., Carlton, V.E., Honigberg, L.A., Schrodi, S.J., Chokkalingam, A.P., Alexander, H.C., et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 75 (2004), 330–337.
255. [255] Hinks, A., Worthington, J., Thomson, W., The association of PTPN22 with rheumatoid arthritis and juvenile idiopathic arthritis. Rheumatology (Oxford) 45 (2006), 365–368.
256. [256] Orozco, G., Sánchez, E., González-Gay, M.A., López-Nevot, M.A., Torres, B., Cáliz, R., et al. Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 52 (2005), 219–224.
257. [257] Plenge, R.M., Seielstad, M., Padyukov, L., Lee, A.T., Remmers, E.F., Ding, B., et al. TRAF1-C5 as a risk locus for rheumatoid arthritis-a genomewide study. N Engl J Med 357 (2007), 1199–1209.
258. [258] Barton, A., Thomson, W., Ke, X., Eyre, S., Hinks, A., Bowes, J., et al. Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. Hum Mol Genet 17 (2008), 2274–2279.
259. [259] Orozco, G., Alizadeh, B.Z., Delgado-Vega, A.M., González-Gay, M.A., Balsa, A., Pascual-Salcedo, D., et al. Association of STAT4 with rheumatoid arthritis: a replication study in three European populations. Arthritis Rheum 58 (2008), 1974–1980.
260. [260] Remmers, E.F., Plenge, R.M., Lee, A.T., Graham, R.R., Hom, G., Behrens, T.W., et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 357 (2007), 977–986.
261. [261] Palomino-Morales, R., Gonzalez-Juanatey, C., Vazquez-Rodriguez, T.R., Rodriguez, L., Miranda-Filloy, J.A., Pascual-Salcedo, D., et al. Lack of association of PTPN22, STAT4 and TRAF1/C5 gene polymorphisms with cardiovascular risk in rheumatoid arthritis. Clin Exp Rheumatol 28 (2010), 695–701.
262. [262] van Nies, J.A., Marques, R.B., Trompet, S., de Jong, Z., Kurreeman, F.A., Toes, R.E., et al. TRAF1/C5 polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies. Arthritis Res Ther, 12, 2010, R38.
263. [263] Bis, J.C., Kavousi, M., Franceschini, N., Isaacs, A., Abecasis, G.R., Schminke, U., et al. Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. Nat Genet 43 (2011), 940–947.
264. [264] López-Mejías, R., Genre, F., García-Bermúdez, M., Ubilla, B., Castañeda, S., Llorca, J., et al. Lack of association between ABO, PPAP2B, ADAMST7, PIK3CG, and EDNRA and carotid intima–media thickness, carotid plaques, and cardiovascular disease in patients with rheumatoid arthritis. Mediators Inflamm, 2014, 2014, 756279.
265. [265] Schunkert, H., König, I.R., Kathiresan, S., Reilly, M.P., AssiMetS, T.L., Holm, H., et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 43 (2011), 333–338.
266. [266] Ibrahim, I., Humphreys, J., Mokhtar, I., Marshall, T., Verstappen, S., Symmons, D., et al. Association of chemokine CXC ligand 12 gene polymorphism (rs1746048) with cardiovascular mortality in patients with rheumatoid arthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis 74 (2015), 2099–2102.
267. [267] López-Mejías, R., Genre, F., García-Bermúdez, M., Corrales, A., González-Juanatey, C., Llorca, J., et al. The ZC3HC1 rs11556924 polymorphism is associated with increased carotid intima–media thickness in patients with rheumatoid arthritis. Arthritis Res Ther, 15, 2013, R152.
268. [268] López-Mejías, R., González-Juanatey, C., García-Bermúdez, M., Castañeda, S., Miranda-Filloy, J.A., Blanco, R., et al. The lp13.3 genomic region -rs599839- is associated with endothelial dysfunction in patients with rheumatoid arthritis. Arthritis Res Ther, 14, 2012, R42.
269. [269] García-Bermúdez, M., López-Mejías, R., González-Juanatey, C., Corrales, A., Castañeda, S., Miranda-Filloy, J.A., et al. Association study of MIA3 rs17465637 polymorphism with cardiovascular disease in rheumatoid arthritis patients. DNA Cell Biol 31 (2012), 1412–1417.
270. [270] López-Mejías, R., García-Bermúdez, M., González-Juanatey, C., Castañeda, S., Miranda-Filloy, J.A., Gómez-Vaquero, C., et al. Lack of association between the CXCL12 rs501120 polymorphism and cardiovascular disease in Spanish patients with rheumatoid arthritis. Hum Immunol 73 (2012), 543–546.
271. [271] López-Mejías, R., Genre, F., García-Bermúdez, M., Castañeda, S., González-Juanatey, C., Llorca, J., et al. The 11q23.3 genomic region-rs964184-is associated with cardiovascular disease in patients with rheumatoid arthritis. Tissue Antigens 82 (2013), 344–347.
272. [272] Lettre, G., Rioux, J.D., Autoimmune diseases: insights from genome-wide association studies. Hum Mol Genet 17 (2008), R116–R121.
273. [273] Xavier, R.J., Rioux, J.D., Genome-wide association studies: a new window into immune-mediated diseases. Nat Rev Immunol 8 (2008), 631–643.
274. [274] Cortes, A., Brown, M.A., Promise and pitfalls of the Immunochip. Arthritis Res Ther, 13, 2011, 101.
275. [275] McCarthy, M.I., Abecasis, G.R., Cardon, L.R., Goldstein, D.B., Little, J., Ioannidis, J.P., et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 9 (2008), 356–369.
276. [276] Kruglyak, L., The road to genome-wide association studies. Nat Rev Genet 9 (2008), 314–318.
277. [277] Wellcome Trust Case Control Consortium, Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature 447 (2007), 661–678.
278. [278] Plenge, R.M., Cotsapas, C., Davies, L., Price, A.L., de Bakker, P.I., Maller, J., et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 39 (2007), 1477–1482.
279. [279] Reilly, M.P., Wolfe, M.L., Rhodes, T., Girman, C., Mehta, N., Rader, D.J., Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 110 (2004), 803–809.
280. [280] Reilly, M.P., Rader, D.J., The metabolic syndrome: more than the sum of its parts?. Circulation 108 (2003), 1546–1551.
281. [281] Mottillo, S., Filion, K.B., Genest, J., Joseph, L., Pilote, L., Poirier, P., et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 56 (2010), 1113–1132.
282. [282] Pereira, R.M., de Carvalho, J.F., Bonfá, E., Metabolic syndrome in rheumatological diseases. Autoimmun Rev 8 (2009), 415–419.
283. [283] Sidiropoulos, P.I., Karvounaris, S.A., Boumpas, D.T., Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications. Arthritis Res Ther, 10, 2008, 207.
284. [284] Chung, C.P., Oeser, A., Solus, J.F., Avalos, I., Gebretsadik, T., Shintani, A., et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 196 (2008), 756–763.
285. [285] Gremese, E., Ferraccioli, G., The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev 10 (2011), 582–589.
286. [286] Härle, P., Sarzi-Puttini, P., Cutolo, M., Straub, R.H., No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 65 (2006), 970–971.
287. [287] González-Gay, M.A., González-Juanatey, C., Rheumatoid arthritis: obesity impairs efficacy of anti-TNF therapy in patients with RA. Nat Rev Rheumatol 8 (2012), 641–642.
288. [288] Senn, J.J., Klover, P.J., Nowak, I.A., Mooney, R.A., Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51 (2002), 3391–3399.
289. [289] Kristiansen, O.P., Mandrup-Poulsen, T., Interleukin-6 and diabetes: the good, the bad, or the indifferent?. Diabetes 54 (2005), S114–S124.
290. [290] Nishida, H., Horio, T., Suzuki, Y., Iwashima, Y., Tokudome, T., Yoshihara, F., et al. Interleukin-6 as an independent predictor of future cardiovascular events in high-risk Japanese patients: comparison with C-reactive protein. Cytokine 53 (2011), 342–346.
291. [291] Dessein, P.H., Joffe, B.I., Singh, S., Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 7 (2005), R634–R643.
292. [292] Dessein, P.H., Joffe, B.I., Suppression of circulating interleukin-6 concentrations is associated with decreased endothelial activation in rheumatoid arthritis. Clin Exp Rheumatol 24 (2006), 161–167.
293. [293] Gonzalez-Gay, M.A., Garcia-Unzueta, M.T., Berja, A., Vazquez-Rodriguez, T.R., Gonzalez-Juanatey, C., de Matias, J.M., et al. Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis. Ann Rheum Dis 67 (2008), 1644–1646.
294. [294] Gonzalez-Gay, M.A., Gonzalez-Juanatey, C., Rodriguez-Rodriguez, L., Miranda-Filloy, J.A., Martin, J., Llorca, J., Lack of association between adipokines and ghrelin and carotid intima–media thickness in patients with severe rheumatoid arthritis. Clin Exp Rheumatol 29 (2011), 358–359.
295. [295] Dessein, P.H., Woodiwiss, A.J., Norton, G.R., Tsang, L., Solomon, A., Independent associations of total and high molecular weight adiponectin with cardiometabolic risk and surrogate markers of enhanced early atherogenesis in black and white patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther, 15, 2013, R128.
296. [296] Rho, Y.H., Chung, C.P., Solus, J.F., Raggi, P., Oeser, A., Gebretsadik, T., et al. Adipocytokines, insulin resistance, and coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 62 (2010), 1259–1264.
297. [297] Dessein, P.H., Tsang, L., Solomon, A., Woodiwiss, A.J., Millen, A.M., Norton, G.R., Adiponectin and atherosclerosis in rheumatoid arthritis. Mediators Inflamm, 2014, 2014, 358949.
298. [298] Kang, Y., Park, H.J., Kang, M.I., Lee, H.S., Lee, S.W., Lee, S.K., et al. Adipokines, inflammation, insulin resistance, and carotid atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther, 15, 2013, R194.
299. [299] Migita, K., Maeda, Y., Miyashita, T., Kimura, H., Nakamura, M., Ishibashi, H., et al. The serum levels of resistin in rheumatoid arthritis patients. Clin Exp Rheumatol 24 (2006), 698–701.
300. [300] Senolt, L., Housa, D., Vernerová, Z., Jirásek, T., Svobodová, R., Veigl, D., et al. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 66 (2007), 458–463.
301. [301] Dessein, P.H., Norton, G.R., Woodiwiss, A.J., Solomon, A., Independent relationship between circulating resistin concentrations and endothelial activation in rheumatoid arthritis. Ann Rheum Dis 72 (2013), 1586–1588.
302. [302] Gonzalez-Gay, M.A., Vazquez-Rodriguez, T.R., Garcia-Unzueta, M.T., Berja, A., Miranda-Filloy, J.A., de Matias, J.M., et al. Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy. Clin Exp Rheumatol 28 (2010), 56–62.
303. [303] Ulbrich, H., Eriksson, E.E., Lindbom, L., Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol Sci 24 (2003), 640–647.
304. [304] Hwang, S.J., Ballantyne, C.M., Sharrett, A.R., Smith, L.C., Davis, C.E., Gotto, A.M. Jr., et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96 (1997), 4219–4225.
305. [305] Malik, I., Danesh, J., Whincup, P., Bhatia, V., Papacosta, O., Walker, M., et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 358 (2001), 971–976.
306. [306] Gonzalez-Gay, M.A., Garcia-Unzueta, M.T., De Matias, J.M., Gonzalez-Juanatey, C., Garcia-Porrua, C., Sanchez-Andrade, A., et al. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 24 (2006), 373–379.
307. [307] González-Gay, M.A., González-Juanatey, C., Miranda-Filloy, J.A., García-Unzueta, M.T., Llorca, J., Lack of association between carotid intima–media wall thickness and carotid plaques and markers of endothelial cell activation in rheumatoid arthritis patients undergoing anti-TNF therapy. Acta Reumatol Port 37 (2012), 155–159.
308. [308] Westra, J., de Groot, L., Plaxton, S.L., Brouwer, E., Posthumus, M.D., Kallenberg, C.G., et al. Angiopoietin-2 is highly correlated with inflammation and disease activity in recent-onset rheumatoid arthritis and could be predictive for cardiovascular disease. Rheumatology (Oxford) 50 (2011), 665–673.
309. [309] Pousa, I.D., Maté, J., Salcedo-Mora, X., Abreu, M.T., Moreno-Otero, R., Gisbert, J.P., Role of vascular endothelial growth factor and angiopoietin systems in serum of Crohn's disease patients. Inflamm Bowel Dis 14 (2008), 61–67.
310. [310] Tsigkos, S., Koutsilieris, M., Papapetropoulos, A., Angiopoietins in angiogenesis and beyond. Expert Opin Investig Drugs 12 (2003), 933–941.
311. [311] López-Mejías, R., Corrales, A., Genre, F., Hernández, J.L., Ochoa, R., Blanco, R., et al. Angiopoietin-2 serum levels correlate with severity, early onset and cardiovascular disease in patients with rheumatoid arthritis. Clin Exp Rheumatol 31 (2013), 761–766.
312. [312] Corallini, F., Bossi, F., Gonelli, A., Tripodo, C., Castellino, G., Mollnes, T.E., et al. The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis. Rheumatology (Oxford) 48 (2009), 293–298.
313. [313] Ziolkowska, M., Kurowska, M., Radzikowska, A., Luszczykiewicz, G., Wiland, P., Dziewczopolski, W., et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 46 (2002), 1744–1753.
314. [314] Asanuma, Y.F., Shimada, Y., Kouzu, N., Yokota, K., Nakajima, K., Sato, K., et al. Serum osteoprotegerin concentration is associated with carotid atherosclerotic plaque in patients with rheumatoid arthritis. Mod Rheumatol 23 (2013), 269–275.
315. [315] Dessein, P.H., López-Mejias, R., González-Juanatey, C., Genre, F., Miranda-Filloy, J.A., Llorca, J., et al. Independent relationship of osteoprotegerin concentrations with endothelial activation and carotid atherosclerosis in patients with severe rheumatoid arthritis. J Rheumatol 41 (2014), 429–436.
316. [316] López-Mejias, R., Ubilla, B., Genre, F., Corrales, A., Hernández, J.L., Ferraz-Amaro, I., et al. Osteoprotegerin concentrations relate independently to established cardiovascular disease in rheumatoid arthritis. J Rheumatol 42 (2015), 39–45.
317. [317] Di Bartolo, B.A., Cartland, S.P., Harith, H.H., Bobryshev, Y.V., Schoppet, M., Kavurma, M.M., TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL. PLoS One, 8, 2013, e74211.
318. [318] Secchiero, P., Corallini, F., Beltrami, A.P., Ceconi, C., Bonasia, V., Di Chiara, A., et al. An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis 210 (2010), 274–277.
319. [319] Secchiero, P., Rimondi, E., di Iasio, M.G., Agnoletto, C., Melloni, E., Volpi, I., et al. C-Reactive protein downregulates TRAIL expression in human peripheral monocytes via an Egr-1-dependent pathway. Clin Cancer Res 19 (2013), 1949–1959.
320. [320] Brombo, G., Volpato, S., Secchiero, P., Passaro, A., Bosi, C., Zuliani, G., et al. Association of soluble Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL) with central adiposity and low-density lipoprotein cholesterol. PLoS One, 8, 2013, e58225.
321. [321] Niessner, A., Hohensinner, P.J., Rychli, K., Neuhold, S., Zorn, G., Richter, B., et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 30 (2009), 789–796.
322. [322] Osmancik, P., Teringova, E., Tousek, P., Paulu, P., Widimsky, P., Prognostic value of TNF-related apoptosis inducing ligand (TRAIL) in acute coronary syndrome patients. PLoS One, 8, 2013, e53860.
323. [323] Secchiero, P., Corallini, F., Ceconi, C., Parrinello, G., Volpato, S., Ferrari, R., et al. Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PLoS One, 4, 2009, e4442.
324. [324] Audo, R., Combe, B., Hahne, M., Morel, J., The two directions of TNF-related apoptosis-inducing ligand in rheumatoid arthritis. Cytokine 63 (2013), 81–90.
325. [325] Dessein, P.H., Lopez-Mejias, R., Ubilla, B., Genre, F., Corrales, A., Hernandez, J.L., et al. TNF-related apoptosis-inducing ligand and cardiovascular disease in rheumatoid arthritis. Clin Exp Rheumatol 33 (2015), 491–497.
326. [326] Dimitroulas, T., Hodson, J., Sandoo, A., Smith, J., Kitas, G.D., Symmetric dimethylarginine (SDMA) serum levels in rheumatoid arthritis: correlations with insulin resistance and disease activity scores. Amino Acids 47 (2015), 1995–2004.
327. [327] Sibal, L., Agarwal, S.C., Home, P.D., Boger, R.H., The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev 6 (2010), 82–90.
328. [328] Böger, R.H., The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 59 (2003), 824–833.
329. [329] Surdacki, A., Nowicki, M., Sandmann, J., Tsikas, D., Boeger, R.H., Bode-Boeger, S.M., et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33 (1999), 652–658.
330. [330] Lundman, P., Eriksson, M.J., Stühlinger, M., Cooke, J.P., Hamsten, A., Tornvall, P., Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 38 (2001), 111–116.
331. [331] Böger, R.H., Bode-Böger, S.M., Szuba, A., Tsao, P.S., Chan, J.R., Tangphao, O., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98 (1998), 1842–1847.
332. [332] Abbasi, F., Asagmi, T., Cooke, J.P., Lamendola, C., McLaughlin, T., Reaven, G.M., et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 88 (2001), 1201–1203.
333. [333] Stühlinger, M.C., Abbasi, F., Chu, J.W., Lamendola, C., McLaughlin, T.L., Cooke, J.P., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287 (2002), 1420–1426.
334. [334] Di Franco, M., Spinelli, F.R., Metere, A., Gerardi, M.C., Conti, V., Boccalini, F., et al. Serum levels of asymmetric dimethylarginine and apelin as potential markers of vascular endothelial dysfunction in early rheumatoid arthritis. Mediators Inflamm, 2012, 2012, 347268.
335. [335] Kwaśny-Krochin, B., Głuszko, P., Undas, A., Plasma asymmetric dimethylarginine in active rheumatoid arthritis: links with oxidative stress and inflammation. Pol Arch Med Wewn 122 (2012), 270–276.
336. [336] Schepers, E., Glorieux, G., Dhondt, A., Leybaert, L., Vanholder, R., Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol Dial Transplant 24 (2009), 1429–1435.
337. [337] Siegerink, B., Maas, R., Vossen, C.Y., Schwedhelm, E., Koenig, W., Böger, R., et al. Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study. Clin Res Cardiol 102 (2013), 193–202.
338. [338] Schulze, F., Carter, A.M., Schwedhelm, E., Ajjan, R., Maas, R., von Holten, R.A., et al. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis 208 (2010), 518–523.
339. [339] Schwedhelm, E., Wallaschofski, H., Atzler, D., Dörr, M., Nauck, M., Völker, U., et al. Incidence of all-cause and cardiovascular mortality predicted by symmetric dimethylarginine in the population-based study of health in pomerania. PLoS One, 9, 2014, e96875.
340. [340] Dimitroulas, T., Hodson, J., Sandoo, A., Smith, J.P., Douglas, K.M., Kitas, G.D., Symmetric dimethylarginine is not associated with cumulative inflammatory load or classical cardiovascular risk factors in rheumatoid arthritis: a 6-year follow-up study. Mediators Inflamm, 2015, 2015, 796562.
341. [341] Gabriel, S.E., Michaud, K., Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther, 11, 2009, 229.
342. [342] Boonen, A., Severens, J.L., The burden of illness of rheumatoid arthritis. Clin Rheumatol 30 (2011), S3–S8.
343. [343] Kvien, T.K., Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22 (2004), 1–12.
344. [344] Doran, M.F., Pond, G.R., Crowson, C.S., O'Fallon, W.M., Gabriel, S.E., Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 46 (2002), 625–631.
345. [345] Gabriel, S.E., Crowson, C.S., O'Fallon, W.M., Mortality in rheumatoid arthritis: have we made an impact in 4 decades?. J Rheumatol 26 (1999), 2529–2533.
346. [346] Jacobsson, L.T., Hanson, R.L., Knowler, W.C., Pillemer, S., Pettitt, D.J., McCance, D.R., et al. Decreasing incidence and prevalence of rheumatoid arthritis in Pima Indians over a twenty-five-year period. Arthritis Rheum 37 (1994), 1158–1165.
347. [347] Krause, D., Schleusser, B., Herborn, G., Rau, R., Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 43 (2000), 14–21.
348. [348] Kvalvik, A.G., Jones, M.A., Symmons, D.P., Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scand J Rheumatol 29 (2000), 29–37.
349. [349] Riise, T., Jacobsen, B.K., Gran, J.T., Haga, H.J., Arnesen, E., Total mortality is increased in rheumatoid arthritis. A 17-year prospective study. Clin Rheumatol 20 (2001), 123–127.
350. [350] Young, A., Koduri, G., Batley, M., Kulinskaya, E., Gough, A., Norton, S., et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 46 (2007), 350–357.
351. [351] Gonzalez-Gay, M.A., Gonzalez-Juanatey, C., Miranda-Filloy, J.A., Garcia-Porrua, C., Llorca, J., Martin, J., Cardiovascular disease in rheumatoid arthritis. Biomed Pharmacother 60 (2006), 673–677.
352. [352] Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Z., Verschuren, W.M., et al., Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice; European Association for Cardiovascular Prevention and Rehabilitation, European Guidelines on cardiovascular disease prevention in clinical practice (version2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis 223 (2012), 1–68.
353. [353] Greenland, P., Alpert, J.S., Beller, G.A., Benjamin, E.J., Budoff, M.J., Fayad, Z.A., et al., American College of Cardiology Foundation; American Heart Association, 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 56 (2010), e50–103.
354. [354] D'Agostino, R.B. Sr., Vasan, R.S., Pencina, M.J., Wolf, P.A., Cobain, M., Massaro, J.M., et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117 (2008), 743–753.
355. [355] Arts, E.E., Popa, C., Den Broeder, A.A., Semb, A.G., Toms, T., Kitas, G.D., et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis 74 (2015), 668–674.
356. [356] Peters, M.J., Symmons, D.P., McCarey, D., Dijkmans, B.A., Nicola, P., Kvien, T.K., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69 (2010), 325–331.